No matches

Educational Resources

Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

Dermatology

5 min

expert video

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

Barrier disruption in AD and the development of environmental and food allergies

Dermatology

5 min

expert video

Barrier disruption in AD and the development of environmental and food allergies

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

Rhinology

9 min

expert video

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

Rhinology

9 min

expert video

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

Pulmonology

5 min

interactivity

Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation

Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

Dermatology

2 min

expert video

Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Dermatology

2 min

expert video

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Most Burdensome Symptoms Rated by PN Patients

Dermatology

1 min

expert video

Most Burdensome Symptoms Rated by PN Patients

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BahrainChange country/region

Educational Resources

Emerging Data on Advanced Systemic Treatments for Children With AD

A brief overview of the pathophysiology of PN

Describing Disease Control in PN

Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

Barrier disruption in AD and the development of environmental and food allergies

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation

Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Most Burdensome Symptoms Rated by PN Patients

Educational Resources

Emerging Data on Advanced Systemic Treatments for Children With AD

A brief overview of the pathophysiology of PN

Describing Disease Control in PN

Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

Barrier disruption in AD and the development of environmental and food allergies

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation

Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Most Burdensome Symptoms Rated by PN Patients